Cost-effectiveness analysis of Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray in treatment of chronic rhinosinusitis / 中国中药杂志

This study aims to evaluate the effectiveness and economic efficiency of Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray in the treatment of chronic rhinosinusitis(CRS). The randomized controlled trial(RCT) of Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray in the treatment of CRS was searched against EMbase, PubMed, Cochrane Library, CNKI, VIP, SinoMed, and Wanfang. The efficacy, nasal mucociliary transport time, and safety of the therapy above in the treatment of CRS were analyzed with single-group rate and Meta-analysis, and the economy and sensitivity were evaluated from the perspective of payer. A total of 9 RCTs were included, including 1 145 patients. Meta-analysis showed that compared with Triamcinolone Acetonide Nasal Spray alone, Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray in the treatment of CRS patients increased the effective rate(RR=1.17, 95%CI[1.11, 1.24], P<0.000 01) and shortened the nasal mucociliary transport time(MD=-3.32, 95%CI[-5.86,-0.78], P=0.01), there was no significant difference in the incidence of adverse reactions between the two groups. The incremental cost-effectiveness analysis showed that the treatment costs of the control group and the observation group were 44.15 yuan and 1 044.96 yuan, respectively. In the Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray treatment group, 75.48 yuan was spent to improve the effective rate of CRS by 1%. The one-way sensitivity analysis indicated the days of treatment, the RR of Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray, the price of unit preparation of Biyuan Tongqiao Granules, and the effective rate of Triamcinolone Acetonide Nasal Spray alone had great influence on the incremental cost-effectiveness ratio. In conclusion, Biyuan Tongqiao Granules combined with Triamcinolone Acetonide Nasal Spray improves the therapeutic effect on CRS. The probabilistic sensitivity analysis showed that when the willingness to pay was greater than 7 920 yuan(less than 0.1 of GDP per capita 8 098 yuan), the combined therapy was economically superior to the control. Due to the limited number of articles published, it is necessary to carry out a real-world clinical trial of Biyuan Tongqiao Gra-nules and Triamcinolone Acetonide Nasal Spray in the treatment of CRS, so as to compare the cost-effectiveness of Biyuan Tongqiao Granules and Triamcinolone Acetonide Nasal Spray.

Inyección intravítrea de bevacizumab vs. acetato de triamcinolona en el edema macular secundario a oclusión de rama venosa retiniana / Intravitreal bevacizumab vs. triamcinolone acetonide injection to treat macular edema secondary to branch retinal vein occlusion

Objetivo: comparar los resultados del tratamiento intravítreo de bevacizumab y de acetato de triamcinolona en el edema macular secundario ante la oclusión de rama venosa retiniana. Métodos: estudio prospectivo, intervencional, aleatorio y comparativo realizado en 34 pacientes. El grupo 1 (16 pacientes) con inyección intravítrea de acetato de triamcinolona y el grupo 2 (18 pacientes) con inyección de bevacizumab hasta completar 3 dosis en cada grupo, seguida la tercera dosis de grid macular. La dosis inicial fue a los 3 meses de la afección, y la evaluación final a los 12 meses. Se evaluó la agudeza visual mejor corregida (Snellen), grosor macular y complicaciones. Resultados: en el grupo 1 la mejor agudeza visual con corrección evolucionó de 0,29 (0,05-0,5) a 0,64 (0,05-1,0); en el grupo 2 de 0,24 (0,05-0,5) a 0,66 (0,11,0). El grosor macular en el grupo 1, de 551,3 (346-967) micras, mejoró a 204,06 (112-449) micras; en el grupo 2, de 546,2 (283-1020) micras, hasta un grosor retinal foveal de 181,05 (112-312) micras. Como complicaciones, en el grupo 1 hubo un incremento de la tensión ocular en el 25,0 por ciento de los pacientes y una progresión de catarata en el 12,5 por ciento. Conclusiones: el tratamiento de inyección intravítrea de bevacizumab en el edema macular secundario a oclusiones venosas de rama retiniana muestra mejor resultado que el de acetato de triamcinolona. También son menores las complicaciones asociadas al bevacizumab(AU)

Objective: to compare the results of the intravitreal treatment with bevacizumab and with triamcinolone acetonide in the macular edema secondary to branch retinal vein occlusion. Methods: a prospective, interventional, random and comparative study was carried out in 34 patients. The first group (16 patients) received intravitreal triamcinolone acetonide injection whereas the second group (18 patients) had bevacizumab injection up to completing three doses in each group, followed by a third dose of macular grid. The initial dose was applied three months after the occurrence of edema and the final evaluation was made 12 months afterwards. Best corrected visual acuity (Snellen's chart), the macular thickness and complications were assessed. Results: in the first group, the best corrected visual acuity increased from 0,29 (0,05-05) to 0,64 (0,05-1,0) whereas in the second group it went from 0,24 (0,05-05) to 0,66 (0,1-1,0).The macular thickness of 551,3 (346-967) microns of the first group improved when reaching 204,06 (112-449) microns and that of the second group went from 546,2 (283-1020) microns to 181,05 (112-312) microns. As to the complications, 25 percent of patients of the first group experienced eye hypertension, and 12,5 percent of patients in the same group had cataract progression. Conclusions: intravitreal bevacizumab injection treatment of the macular edema secondary to branch retinal vein occlusion was better than that based on triamcinolone acetonide injection. The complications associated to bevacizumab treatment were fewer(AU)

Dermoscopic evaluation of therapeutic response to an intralesional corticosteroid in the treatment of alopecia areata.

Background: Intralesional corticosteroids are the treatment of choice for adults with less than 50% of scalp area involvement with alopecia areata. The sensitivity of picking up clinical response to treatment by clinical examination is very variable and has inter individual variation. Aims: To evaluate the efficacy of intralesional triamcinolone acetonide in the treatment of alopecia areata and to use dermoscopy to identify signs of early clinical response and adverse effects. Methods: Seventy patches in 60 patients were injected with steroid at 4 weeks interval and followed up for 24 weeks. Treatment response was evaluated using regrowth scale (RGS). Heine DELTA 20; dermatoscope was used to assess disease activity, response to treatment and side effects. Results: Twenty eight patients responded early and achieved RGS of 4 within 12 weeks and 29 patients responded late and achieved RGS of 4 within 24 weeks of initiating therapy. There were 3 patients who did not achieve RGS of 4 at 24 weeks. Late and incomplete responders showed statistically significant association with family history of alopecia areata (p < 0.0001), presence of recurrent disease (p = 0.0147) and presence of nail changes (p = 0.0007). Dermoscopically, 60 patches demonstrated regrowth of new vellus hair at 4 weeks. Tapering hair disappeared maximally at 4 weeks. At 12 weeks, complete disappearance was seen in tapering hairs, broken hairs and black dots whereas for yellow dots to disappear completely in all patches it took 16 weeks. The adverse effects were observed at an earlier stage using dermoscopy than clinically. Conclusion: Intralesional triamcinolone acetonide is efficacious for treatment of localized patchy alopecia areata. Dermoscopy is very useful to identify signs of early clinical response, adverse effects and markers of disease activity.

Fulminant toxoplasmic retino-choroiditis following intravitreal triamcinolone administration.

We report two cases of fulminant toxoplasmic retinochoroiditis following intravitreal triamcinolone acetonide (IVTA) administration. Case 1: A 42-year-old female received IVTA for presumed non-infectious panuveitis. Within 2 months, she developed diffuse macular retinochoroiditis with optic disc edema. Upon starting anti-toxoplasmic therapy (ATT), her intraocular inflammation resolved with catastrophic damage to the disc and macula. Case 2: A 30-year-old male received IVTA for presumed reactivation of previously scarred toxoplasmic retinochoroiditis. Despite simultaneous ATT, within 6 weeks, he developed extensive, multifocal macular retinochoroiditis. He continued to require ATT for 18 months and later underwent vitrectomy with silicone oil placement for severe epiretinal proliferation. Aqueous tap polymerase chain reactions were found positive for Toxoplasma gondii in both cases. In conclusion, IVTA administration can lead to fulminant toxoplasmic retinochoroiditis even when used with appropriate ATT. Extreme caution should be exercised while administering depot corticosteroids in eyes with panuveitis of unknown origin.

Residual triamcinolone acetonide at macular hole after vitreous surgery.

Post traumatic macular holes have shown successful anatomic outcomes with vitrectomy with internal limiting membrane (ILM) peeling and gas injection. Intraocular use of triamcinolone acetonide (TA) crystals is gaining popularity in patients for visualization of the vitreous cortex, posterior vitreous detachment induction and ILM peeling during macular hole surgery. However, the possibility of residual steroid crystals clogging the hole at the conclusion of surgery exists. In our case, residual TA was observed biomicroscopically in the fovea on the seventh day after surgery, Optical Coherence Tomography (OCT) image of the eye showed a hyper reflective mass corresponding to the TA. However, a repeat OCT carried out four weeks after surgery showed recovery of the foveal morphologic features to an almost normal depression, with closure of the hole. Residual TA crystals in the macular hole post vitreous surgery may not interfere with ultimate macular hole closure or visual improvement.

Avaliação da acuidade visual e da pressão intraocular no tratamento do edema macular diabético com triancinolona intravítrea / Study of visual acuity and intraocular pressure in the treatment of macular diabetic edema with intravitreous triamcinolone

OBJETIVOS: Avaliar os efeitos do acetato de triancinolona intravítreo em pacientes com edema macular diabético difuso na acuidade visual e pressão intraocular. Relatar os possíveis efeitos adversos e analisar a possível relação da idade dos pacientes com as variações da acuidade visual e pressão intraocular. MÉTODOS: O ensaio clínico controlado incluiu 14 pacientes (28 olhos), sendo que 14 olhos receberam injeção de 4 mg de acetato de triancinolona intravítreo para o tratamento de edema macular diabético difuso. O grupo tratado foi comparado a um grupo controle de 14 olhos sem edema macular diabético difuso. O tempo de seguimento foi de três meses. RESULTADOS: Os picos de pressão intraocular >21 mmHg ocorreram em 28,57 por cento, com diferença significante entre a pressão intraocular do grupo tratado com o grupo controle na primeira semana após o tratamento. A acuidade visual mostrou uma significativa melhora quando comparada com o grupo controle desde o segundo dia após o tratamento. Não houve associação entre a idade com as variações da acuidade visual e a pressão intraocular. CONCLUSÃO: O acetato de triancinolona intravítreo mostrou-se ser eficiente para melhorar a acuidade visual em pacientes com edema macular diabético difuso, nos primeiros três meses de tratamento. A incidência de hipertensão intraocular foi de 28,57 por cento, podendo ser caracterizada como de fácil controle.

PURPOSE: To evaluate the effect of intravitreal triamcinolone acetonide in patients with diffuse diabetic macular edema on the visual acuity and intraocular pressure. To report the potential adverse events and to analyze the potential relationship between age and visual acuity and intraocular pressure variability. METHODS: This clinical controlled study included 14 patients (28 eyes), 14 of the eyes received an intravitreal injection of 4 mg triamcinolone acetonide for the treatment of diabetic macular edema. The study group was compared to a control group of 14 eyes, without diabetic macular edema. The follow-up period was of 3 months. RESULTS: Pressure spikes >21 mmHg occurred in 28.7 percent of eyes, with a significant difference of intraocular pressure between the study group and the control group in the first week after treatment. Visual acuity showed a significant improvement when compared with the control group since the second day after the treatment. There was no association between age and variability of visual acuity and intraocular pressure. CONCLUSION: Intravitreal triamcinolone acetonide showed to be effective for improving visual acuity in patients with diabetic macular edema, in the first three months of treatment. The incidence of intraocular hypertension was 28.7 percent, easily manageable.

Effectiveness of radiation synovectomy with samarium-153 particulate hydroxyapatite in rheumatoid arthritis patients with knee synovitis: a controlled randomized double-blind trial

OBJECTIVES: The aim of the present study was to investigate the effectiveness of Samarium153-particulate hydroxyapatite radiation synovectomy in rheumatoid arthritis patients with chronic knee synovitis. METHODS: Fifty-eight rheumatoid arthritis patients (60 knees) with chronic knee synovitis participated in a controlled double-blinded trial. Patients were randomized to receive either an intra-articular injection with 40 mg triamcinolone hexacetonide alone (TH group) or 40 mg triamcinolone hexacetonide combined with 15 mCi Samarium153-particulate hydroxyapatite (Sm/TH group). Blinded examination at baseline (T0) and at 1 (T1), 4 (T4), 12 (T12), 32 (T32), and 48 (T48) weeks post-intervention were performed on all patients and included a visual analog scale for joint pain and swelling as well as data on morning stiffness, flexion, extension, knee circumference, Likert scale of improvement, percentage of improvement, SF-36 generic quality of life questionnaire, Stanford Health Assessment Questionnaire (HAQ), Lequesne index, use of non-steroidal anti-inflammatory drugs or oral corticosteroids, events and adverse effects, calls to the physician, and hospital visits. RESULTS: The sample was homogeneous at baseline, and there were no withdrawals. Improvement was observed in both groups in relation to T0, but no statistically significant differences between groups were observed regarding all variables at the time points studied. The Sm/TH group exhibited more adverse effects at T1 (p<0.05), but these were mild and transitory. No severe adverse effects were reported during follow-up. CONCLUSION: Intra-articular injection of Samarium153-particulate hydroxyapatite (15 mCi) with 40 mg of triamcinolone hexacetonide is not superior to triamcinolone hexacetonide alone for the treatment of knee synovitis in patients with rheumatoid arthritis at 1 y of follow-up.

Acute orbital abscess complicating deep posterior subtenon triamcinolone injection.

A 54-year-old diabetic female presented with orbital abscess and corneal infiltrate 3 days after deep posterior subtenon triamcinolone acetonide injection in her right eye. This was administered immediately after focal laser photocoagulation for diabetic macular edema. The orbital abscess and corneal infiltrate responded to systemic and topical antibiotics.

Cytomegalovirus Retinitis After Intravitreous Triamcinolone Injection in a Patient with Central Retinal Vein Occlusion

To report a case of cytomegalovirus (CMV) retinitis after intravitreal injection of triamcinolone acetonide (IVTA). A 77-year-old woman with macular edema due to central retinal vein occlusion (CRVO) developed peripheral retinitis 4 months after IVTA. A diagnostic anterior chamber paracentesis was performed to obtain DNA for a polymerase chain reaction (PCR) test for viral retinitis. The PCR test was positive for CMV DNA. Other tests for infective uveitis and immune competence were negative. Four months after presentation, gancyclovir was intravitreously injected a total of 5 times, and the retinitis resolved completely. CMV retinitis is a rare complication of local immunosuppression with IVTA. It can be managed with timely injection of intravitreal gancyclovir until recovery from local immunosuppression.

Experimental strabismus surgery using triamcinolone: outcomes and effects on inflammatory response

PURPOSE: To evaluate the efficiency of triamcinolone (TRI) in limiting the postoperative inflammatory response and scarring after strabismus surgery. METHODS: A prospective, two-stage, masked, controlled trial was conducted. In the first stage, the inflammatory response at the extraocular muscle reattachment site was analyzed after superior rectus recession in ten rabbits. In the second stage, TRI (40 mg/ml) was applied during surgery to the eyes of 16 rabbits with superior rectus recession. As a control, contralateral eyes were treated with physiological saline. Fifteen days later, exenteration was performed, and the sites of muscle reattachment were processed for histological examinations. The sums of the areas of the granulomas in the extraocular muscle reattachment sites of control and treated eyes were compared. RESULT: There was a preliminary inhibition effect of TRI on the inflammatory response of treated eyes compared with that of control eyes. CONCLUSIONS: In the conditions of conducting this study the introperative use of TRI was effective in controlling the postoperative inflammatory response in rabbit eyes after extraocular muscle surgery.

OBJETIVO: Avaliar a eficiência da triancinolona (TRI) como agente modulador da resposta inflamatória e cicatricial em coelhos submetidos à cirurgia de estrabismo. MÉTODOS: Foi realizado estudo prospectivo, mascarado, em dois estágios. No primeiro estágio 10 coelhos foram submetidos a retrocesso do músculo reto superior em ambos os olhos, aplicando-se triancinolona (40 mg/ml) em um dos olhos e como controle, solução salina nos olhos contralaterais. Quinze dias e trinta dias após, os animais foram exenterados e o material do sítio de reinserção muscular foi submetido à análise qualitativa e quantitativa. No segundo estágio, com incrementação da agressão cirúrgica, 16 coelhos foram submetidos aos mesmos procedimentos com exenteração e análise dos tecidos após 15 dias. RESULTADO: Houve efeito inibitório da TRI na resposta inflamatória dos olhos tratados quando comparados aos olhos-controle. CONCLUSÕES: Nas condições de realização do presente estudo o uso per-operatório da TRI foi efetivo no controle da resposta inflamatória em olhos de coelhos submetidos à cirurgia de estrabismo.

Toxoplasmosis retinochoroiditis after photodynamic therapy and intravitreal triamcinolone for a supposed choroidal neovascularization: a case report

The purpose is to report a complication after photodynamic therapy (PDT) and intravitreal triamcinolone for a presumed choroidal neovascularization in age-related macular degeneration. Photodynamic therapy and intravitreal triamcinolone were used in an 84-year-old man with choroidal neovascularization in the left eye. Forty-five days after therapy, the patient returned with a severe necrotizing uveitis in the posterior pole and vitritis. Laboratory investigation disclosed a high anti-Toxoplasma IgG titer. Therapy with pyrimethamine, sulfadiazine and folinic acid resulted in total lesion healing although central vision was lost. Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient. Although rare, this complication may not be disregarded in the cases that require intraocular corticosteroids for treatment of several conditions, especially in patients who had previously suffered from toxoplasmosis infection.

O objetivo é relatar complicação após terapia fotodinâmica (PDT) e triancinolona intravítrea para presumida neovascularização de coróide em degeneração macular relacionada à idade. A terapia fotodinâmica e triancinolona intravítrea foram utilizados em paciente de 84 anos, do sexo masculino, com neovascularização de coróide no olho esquerdo. Quarenta e cinco dias após o tratamento, o paciente retornou com grave retinite necrosante do pólo posterior e vitreíte. Investigação laboratorial indicou alto título de IgG anti-Toxoplasma. Tratamento com pirimetamina, sulfadiazina e ácido folínico levaram à total cicatrização da lesão embora a visão central tenha sido comprometida. Conclui-se que a triancinolona intravítrea pode ter influenciado na exacerbação da retinocoroidite no pólo posterior do paciente. Embora rara, esta complicação não pode ser descartada nos casos que necessitem corticóide intra-ocular para tratamento de várias doenças, principalmente em pacientes que tenham tido surtos prévios de toxoplasmose ocular.

Avaliação clínica e incidência de endoftalmite infecciosa e não-infecciosa após injeção intravítrea de acetonida de triancinolona / Clinical characteristics and incidence of infectious and non-infectious endophthalmitis after intravitreous injection of triamcinolone acetonide

OBJETIVO: Relatar a incidência de endoftalmite infecciosa e não-infecciosa após injeção intravítrea de 4 mg de triancinolona (Kenalog® - 40 mg/ml; 0,1 ml) e avaliar aspectos clínicos relevantes para o diagnóstico diferencial entre estas duas entidades. Desenho: Estudo prospectivo não-concorrente. MÉTODOS: Foram analisados os prontuários de 121 pacientes (154 injeções) que, consecutivamente, foram submetidos à injeção intravítrea de triancinolona para o tratamento de diversas doenças coriorretinianas. Todas as injeções foram realizadas em centro cirúrgico em condições de assepsia e anti-sepsia, comuns às cirurgias oftalmológicas. RESULTADOS: Nenhum olho apresentou endoftalmite infecciosa. Dois olhos (1,29 por cento/injeção e 1,65 por cento/paciente) apresentaram endoftalmite não-infecciosa caracterizada pela observação, no primeiro dia pós-operatório, de baixa de acuidade visual, hiperemia, hipópio e reação inflamatória no vítreo. Estes dois olhos evoluíram com resolução do quadro inflamatório, após o uso de corticóide tópico e subconjuntival. CONCLUSÕES: Na presente série, nenhum olho apresentou endoftalmite infecciosa. A ocorrência de endoftalmite não-infecciosa após a injeção intravítrea de triancinolona é relativamente rara e, geralmente, pode ser diferenciada da endoftalmite infecciosa por meio da análise criteriosa das suas manifestações clínicas.

PURPOSE: To report the incidence of infectious and noninfectious endophthalmitis after intravitreal injection of 4 mg of triamcinolone acetonide (Kenalog® - 40 mg/ml; 0.1 ml) and to evaluate distinguishing characteristics that may assist the clinician in differentiating these entities. Design: Observational nonconcurrent prospective study. METHODS: Charts of 121 patients (154 injections) who consecutively underwent intravitreal injection of triamcinolone acetonide to treat various chorioretinal diseases were evaluated. All procedures were performed in an operating room with careful antiseptic protocol. RESULTS: Two eyes (1.29 percent/injection and 1.65 percent/patient) presented a noninfectious endophthalmitis characterized by decreased vision, hyperemia, hypopyon and vitreous inflammatory reaction, on the first day after the injection. These eyes were treated with topical and subconjunctival corticosteroids with complete resolution of the inflammatory reaction. CONCLUSION: In the present case series, no case of infectious endophthalmitis occurred. Despite being relatively rare, noninfectious endophthalmitis can be associated with intravitreal injection of triamcinolone simulating an infectious endophthalmitis. In selected cases, the differential diagnosis can be made solely by clinical evaluation.

Acute bilateral central serous chorioretinopathy following intra-articular injection of corticosteroid.

There is increasing evidence in the literature implicating the use of exogenous steroids through various routes as a risk factor for the development of idiopathic central serous chorioretinopathy (ICSC). We report a case of acute bilateral ICSC following intra-articular injection of corticosteroids.

Pseudohypopyon immediately after intravitreal injection of triamcinolone acetonide: case reports

Descrição de dois casos de pacientes submetidos à injeção intravítrea de acetonida de triancinolona (AT), que desenvolveram pseudo-hipópio transitório. Um paciente apresentava edema macular diabético clinicamente significativo com componente cistóide e o outro, com descolamento seroso de retina agudo com Vogt-Koyanagi-Harada, e ambos desenvolveram pseudo-hipópio com presença de depósitos de cristais no endotélio corneano; em um caso o pseudo-hipópio desapareceu espontaneamente em 24 horas, no outro caso o pseudo-hipópio teve duração de 2 dias. O pseudo-hipópio é importante sinal que pode ser observado após injeção intravítrea de AT, em pacientes fácicos, apresentando resolução espontânea sem complicações. Este pseudo-hipópio causado por depósitos de cristais de AT deve ser considerado diagnóstico diferencial para hipópio infeccioso associado a este tipo de tratamento.

Efeito da triancinolona intravítrea na pressão intra-ocular / Effect of intravitreal triamcinolone on intraocular pressure

Objetivo: Estudar o comportamento da pressão intra-ocular após injeção intravítrea de 4mg de acetonido de triancinolona. Métodos: Foram revisados 86 prontuários de pacientes submetidos à injeção intravítrea de triancinolona no periodo de 2002 a 2003. Quarenta olhos de quarenta pacientes que puderam ser acompanhados por pelo menos três meses foram incluídos no estudo. Analizaram-se os seguintes parâmetros: idade, sexo, doença de base, história prévia de glaucoma, cirurgia de catarata prévia e pressão intra-ocular pré e pós-injeção intravítrea de triancinolona. Resultados: A idade média foi 67,5 +/- 15,8 anos. As mulheres constituíram 26 casos (65 por cento). A principal indicação do uso da triancinolona foi a degeneração macular relacionada à idade exsudativa (23 olhos, 57,5 por cento). quatro pacientes (10 por cento) eram portadores de glaucoma. Onze olhos (27,5 por cento) mostraram elevação da pressão intra-ocular (Po) além de 18 mmHg, com aumento de pelo menos 5 mmHg em relação a Po inicual ou diferença de pelo menos 3 mmHg em relaçào ao olho adelfo. Essa elevação da Po se deu entre dois e três meses da injeção da triancinolona em nove pacientes (81,8 por cento). Dois dos quatro pacientes com glaucoma já diagnosticado (50 por cento) mostraram elevação adicional da Po. Conclusão: Cerca de uma quarto dos pacientes submetidos à injeção intravítrea de 4 mg de triancinolona desenvolveram incremento significativo da pressão intra-ocular, geralmente entre dois e três meses após a injeção.

Glucocorticoid-induced laminitis with hepatopathy in a Thoroughbred filly

A 3-year-old Thoroughbred filly was referred to the Equine Hospital, Korea Racing Association for evaluation of hematuria, inappetite, weight loss and depression. From 25 days prior to admission, the horse was treated for right carpal lameness with 20 mg intramuscular administration of triamcinolone acetonide per day for consecutive 10 days by a local veterinarian. Clinical and laboratory findings included vaginal hyperemia, flare in bladder wall, neutrophilia, lymphopenia, polyuria, polydipsia and laminitis in the end. High activities of aspartate transaminase and gamma glutamyltransferase and high concentration of total bilirubin indicated hepatopathy. Further hematology, serum biochemistry and urinalysis did not reveal any abnormalities. Medical history, physical and clinicopathologic findings suggest that the laminitis and hepatopathy in this horse were most likely induced by repeated administration of exogenous corticosteroid. However, guarded prognosis of treating laminitis undermined the benefit of improvement of hematuria following electroacupuncture stimulation. The combined stimulation of kidney related acupoints (Shen Peng, Shen Shu), lumber related acupoints (Yao Qian, Yao Zhong) and associate acupoints (Guan Yuan Shu, Bai Hui) at 5Hz, 1-2V, for 40 minutes was of value in the treatment of hematuria. This case shows that horses under steroids may exhibit laminitis and steroid hepatopathy. Early recognition and good management of laminitis are important in the limitation of complications.

Topical steroid induced chronic demodicidosis.

We report a 39-year-old female patient who developed pruritic erythematous telangiectatic patches with scaly follicular papules on the neck and upper chest for 4 years. Ten per cent potassium hydroxide preparation of skin scrapings revealed Demodex folliculorum. Histology showed three Demodex mites in one of the hair follicles. She was treated with a topical steroid without improvement. The skin lesions and Demodex mite disappeared after a single application of 1 per cent gamma benzene hexachloride but twice daily application of 1 per cent gamma benzene hexachloride for 2 weeks was needed to prevent recurrence.